SUMMARY Background
To optimise treatment of ulcerative colitis (UC), patients need repeated assessment of mucosal inflammation. Current non-invasive biomarkers and clinical activity indices do not accurately reflect disease activity in all patients and cannot discriminate UC from non-UC colitis. Volatile organic compounds (VOCs) in exhaled air could be predictive of active disease or remission in Crohn's disease.
Aim
To investigate whether VOCs are able to differentiate between active UC, UC in remission and non-UC colitis.
Methods UC patients participated in a 1-year study. Clinical activity index, blood, faecal and breath samples were collected at each out-patient visit. Patients with clear defined active faecal calprotectin >250 lg/g and inactive disease (Simple Clinical Colitis Activity Index <3, C-reactive protein <5 mg/L and faecal calprotectin <100 lg/g) were included for cross-sectional analysis. Non-UC colitis was confirmed by stool culture or radiological evaluation. Breath samples were analysed by gas chromatography time-of-flight mass spectrometry and kernel-based method to identify discriminating VOCs.
Results
In total, 72 UC (132 breath samples; 62 active; 70 remission) and 22 non-UCcolitis patients (22 samples) were included. Eleven VOCs predicted active vs. inactive UC in an independent internal validation set with 92% sensitivity and 77% specificity (AUC 0.94). Non-UC colitis patients could be clearly separated from active and inactive UC patients with principal component analysis.
Conclusions
Volatile organic compounds can accurately distinguish active disease from remission in UC and profiles in UC are clearly different from profiles in non-UC colitis patients. VOCs have demonstrated potential as new noninvasive biomarker to monitor inflammation in UC. 
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INTRODUCTION
Ulcerative colitis (UC) is a chronic lifelong inflammatory disease of the colon, characterised by periods of quiescent disease alternated by active inflammation. Regular evaluation of disease activity is mandatory to optimise therapeutic management and reduce the risk of developing complications and to prevent colectomy. Ileocolonoscopy is the current 'gold' standard for assessment of mucosal inflammation in inflammatory bowel disease (IBD) but has several well-known disadvantages, i.e. inconvenient bowel preparation, patient discomfort, risk of complications and considerable costs.
For many years, the cornerstone of non-invasive evaluation of mucosal inflammation has been a symptombased clinical judgement. Clinical activity indices such as the Truelove and Witts Severity Index or Simple Clinical Colitis Activity Index (SCCAI) were developed for systematic evaluation of the outcome of clinical trials in UC. 1, 2 These indices correlate with endoscopic disease activity, but are prone to inter-observer variation and may therefore lead to incorrect classification of remission or active disease. 3 The correlation of symptoms with severity of endoscopic lesions was, however, found to be weaker in case of highly active inflammation, when compared to moderate or low level inflammation. 4 Furthermore, functional irritable bowel syndrome-like symptoms regularly occur in patients with low-grade inflammation or in the absence of endoscopic inflammation, 5, 6 and affect clinical activity scores. Faecal calprotectin is increasingly used in clinical practice as a sensitive marker for endoscopic active disease in UC. [7] [8] [9] [10] [11] [12] However, faecal calprotectin is not specific for IBD-related inflammation. Elevated faecal calprotectin values are also found, for example, after use of nonsteroidal anti-inflammatory drugs and in gastrointestinal infections such as Clostridium difficile or Campylobacter jejuni. [13] [14] [15] and in colonic diverticulitis. 16 Furthermore, many patients are reluctant to collect stool samples. Hence, there is a need for more UC-specific inflammatory markers for exacerbations. A promising new non-invasive method of diagnosing disease is by analyses of volatile organic compounds (VOCs) in exhaled air. 17 Large quantities of VOCs are detected in exhaled breath, which change as a result of aberrant physiological and metabolic processes within the host as well the intestinal microbiota 18 and specific VOCs patterns to diagnose disease states (e.g. chronic obstructive pulmonary disease) have been found. 19, 20 Recently, we identified a sensitive and specific profile consisting of 10 VOCs to diagnose active disease in adults patients with Crohn's disease. 21 In earlier studies, single VOCs like ethane and pentane, which are degradation products of lipid peroxidation, could differentiate between healthy controls and IBD patients, and furthermore, ethane showed correlation with both clinical and endoscopic disease activity in UC. 22, 23 These single VOCs lack however specificity for IBD-related inflammation. So far, a metabolomics approach of exhaled air for the differentiation of active UC vs. UC in remission a well as non-UC colonic inflammation (e.g. infectious colitis or diverticulitis) has not been reported. We hypothesise that specific VOC profiles can be identified in patients with active UC compared to UC patients in remission and non-UC colitis. Therefore, the primary aim of our study was to investigate whether VOC profile analyses in exhaled air can accurately distinguish UC patients with active disease from UC patients in remission, and the secondary aim was to investigate whether VOC profiles are able to distinguish UC patients from non-UC colitis patients.
MATERIALS AND METHODS
Patient inclusion
Consecutive UC patients were recruited during a 15 month time period when visiting the out-patient clinic of the Maastricht University Medical Center+ (MUMC+), and participated in a 1-year follow-up study. All patients had an established diagnosis of UC, based on clinical, endoscopic and histological criteria. 24, 25 Demographic and clinical data were collected using the computer-based registration database. Informed consent was obtained from all patients prior to participation. The study was approved by the Medical Ethics Committee of the MUMC+ (NL24572.018.08).
Clinical activity scores, blood and faecal and breath samples were collected at study entry, at every outpatient visit or when a flare occurred during 1 year of follow-up. Due to ethical considerations it was not possible to perform an endoscopy at every out-patient visit. Therefore, the SCCAI, 2 C-reactive protein (CRP) and faecal calprotectin were used for the assessment of disease activity. It is readily accepted that in the absence of endoscopy as gold standard, a stringent surrogate definition of active disease or remission is needed, which was based on the combination of the clinical activity index, CRP and faecal calprotectin. 21, 26 Active disease was defined by faecal calprotectin ≥250 lg/g, and remission by the combination of SCCAI <3 points and CRP <5 mg/L and faecal calprotectin <100 lg/g. For this study, only patients with clearly defined active disease or remission according to the above described criteria were included and used for cross-sectional analysis.
Patients with non-UC colitis were recruited among inpatients admitted to the gastroenterology ward of the MUMC+. None of these patients was diagnosed with IBD. A diagnosis of infectious colitis was confirmed by a positive stool culture. Diverticulitis was confirmed radiologically with abdominal ultrasound or computed tomography scanning, and elevated CRP and leucocytes. Blood samples for CRP analysis and exhaled air were collected in all patients.
Sampling and analysis of exhaled air
Each subject involved in the study was asked to inflate a 5L tedlar bag (SKC Ltd, Dorset, UK). No dietary restrictions were given prior to sampling, but eating, smoking and exercise were not allowed 1 h before sampling. All patient samples were collected at the same location to prevent background bias. The sampling of the patients was randomised over time of the day. The contents of the bag were transferred to carbon-filled stainless steel sorption tubes (Markes International, Llantrisant Business Park, UK). Until analysis the airtight capped tubes were stored at room temperature. The exhaled air samples were measured by thermal desorption-gas chromatography combined with time-offlight mass spectrometry (GC-tof-MS) as previously described. 17 After separation by GC, the compounds were identified by tof-MS (Thermo Electron Tempus Plus time-of-flight mass spectrometer; Thermo Electron Corporation, Waltham, MA, USA). The experimental settings for GC and tof-MS have been described elsewhere. 20 The chemical identification of the compounds was performed using retention time and mass spectrum. Spectrum recognition was performed using the National Institute of Standards and Technology (NIST) mass spectral library, looking at the similarity between recorded mass spectra and the library mass spectra. 21 Data handling: statistical analysis Before the actual statistical analysis, raw GC-tof-MS chromatograms were pre-processed to diminish the influence of instrumental and analytical disturbances, by denoising, baseline correction, alignment, normalisation and scaling of the data respectively. 20 The chromatograms were divided into three groups: active UC, inactive UC and non-UC colitis patients. The data of the active and inactive UC patients were randomly assigned to a training (80%) and internal validation set (20%). 27, 28 The entire procedure was repeated 1000 times. The training set was used to identify the most discriminatory compounds and subsequent optimisation of the classification model. The aim was to find a set of discriminatory volatile metabolites in breath, for which linear recursive feature elimination (RFE) 29 was used to select the most discriminatory compounds between active and inactive UC. To reveal the classification power of the selected compounds in differentiating active and inactive UC patients, kernel partial least square discriminatory analysis (KPLS-DA) was used on the validation set via the receiver operating characteristic curve (ROC).
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The ROC curve was derived from a KPLS-DA algorithm consisting of a selected set of discriminatory compounds, which gives a probability (a number between 0 and 1) for each patient of being in active or inactive disease stage. Subsequently, these probabilities were used as a range of cut-off values to calculate the sensitivity and specificity displayed in the ROC curve. 30 The final sensitivity and specificity of the classification model was calculated using an optimal cut-off obtained from the training samples. The optimal cut-off was selected as the one which maximises both sensitivity and specificity. We took into account that multiple samples were obtained from the same patient through carefully selecting the training and the independent validation set, that is, the KPLS-DA classification model was never trained on only a part of the samples of the patient and tested on the remaining samples of the same patient. Moreover, to diminish the influence of intra-individual variation, centering per individual was performed. 31, 32 In addition, sensitivity and specificity values were calculated for an individual patient by majority vote, by which a sample was classified to the group with the maximum number of votes across all samples for the patient for active and inactive groups. The tie was treated as undefined group. Finally, the significance of the classification model was assessed using a permutation test with 1000 iterations. 33, 34 In the final step, the compounds selected as discriminatory between active and non-active UC (via RFE) were used in unsupervised random forests (URF) 35 to visualise the differences between active UC, UC patients in remission and non-UC colitis patients. The differences between chromatograms of all three groups were demonstrated using principal component analysis (PCA) performed on the proximity obtained from URF. The proximity matrix contains a similarity score, ranging from 0 to 1, between different individuals. The more similar two chromatograms, the higher, that is, closer to 1, the similarity score is. The URF method is capable of discovering underlying patterns in the data by means of PCA performed on the proximity matrix. The resulting PCA score plot allows visualisation of the relation between all breath-o-grams. In the score plot, each breath sample is symbolised as a point and shows how all samples are related to each other. Hence, the points close to each other have similar VOCs profile, while objects that lie far away are described by different properties. We also investigated whether there is a relation between discriminatory volatile metabolites in breath and the level of faecal calprotectin by means of gradient boosting regression trees. 36 To test whether any of the individual significant VOCs and the discriminatory profiles were statistically influenced by external factors (i.e. gender, smoking habit, disease location and use of medication), we used the Mann-Whitney U test and Kruskal-Wallis test with a Benjamini-Hochberg post hoc correction for multiple testing for testing the individual VOCs, and regularised multivariate analysis of variance (rMANOVA) for testing the VOCs profile. 37 Major differences in dietary intake during periods of active and quiescent disease could have impact on exhaled VOCs, for example by changing the faecal microbiota composition and activity. As in our cohort, no information was available on food intake, the effect of diet was investigated by means of another cohort of 1307 individuals (LifeLines Deep Cohort 38 ), where information on VOCs and specific diet was available. To test the effect of diet on the individual VOCs we used the Mann-Whitney U test with a BenjaminiHochberg post hoc correction for multiple testing.
RESULTS
Patients
In total, 72 UC and 22 non-UC colitis patients were included in this prospective follow-up study. Patient characteristics are listed in Table 1 . During the 1-year follow-up period, 1-5 breath samples were collected per UC patient, resulting in a total of 132 samples. The number of samples collected per patient varied: 34 individuals provided one breath sample, 18 delivered two samples, 10 provided three breath samples, six delivered four breath samples and two patients were sampled five times. Of a total 162 breath samples, n = 62 were collected at a time point of active disease according to our definition of faecal calprotectin >250 lg/g. Median (IQR) values for SCCAI, CRP and faecal calprotectin for samples collected during active disease or remission are given in Table 2 . At time of sampling, E1, E2 and E3 phenotype was found in 6%, 64% and 30%, respectively, of the samples collected during active disease and in 7%, 70% and 23% of remission samples. All non-UC colitis patients had an elevated CRP [median (IQR) 70 
Chromatograms
In total, 154 chromatograms were measured. After data preprocessing, the final 154 chromatograms contained 2509 VOCs. The majority of all available VOCs only occurred in a limited number of samples and had 0 values in most samples. Therefore, a compound was only kept for further analysis if it could be detected in at least 20% of samples in one of the experimental groups. 39 The final data matrix contained 364 VOCs.
VOCs analysis
Active UC vs. UC in remission. The RFE with linear kernel identified a set of 11 VOCs to discriminate between active and inactive UC in the training set. These were then used to build the final KPLS-DA classification model. Using the internal validation set, ROC analysis showed a sensitivity of 0.92, a specificity of 0.77 using an optimal cut-off value of 0.507 and an AUC of 0.94 (95% confidence interval of 0.91-0.97) for the differentiation between active and inactive UC samples (see also Figure S1). As described in the Materials and Methods section, the classification performance for each individual patient can be calculated by taking the maximum number of votes across all samples for that patient for active disease and remission. The sensitivity and specificity calculated on the patient-level reached 0.93 and 0.83, respectively. To further validate the obtained classification KPLS-DA model, a permutation test was carried out using 1000 iterations, which resulted in a P-value of 0.005.
Of the 11 discriminating VOCs, 10 could be chemically identified using the NIST library. The directions of VOC changes and their importance in discriminating disease activity in UC are shown in Figure 1 . The larger the value, the more importance the compound has in distinguishing active from inactive UC. The relative concentrations of VOCs with a positive value were increased in UC patients with active disease and vice versa. No significant effects were found from potential confounding factors [i.e. smoking, gender, disease location and medication (mesalazines, corticosteroids, thiopurines, methotrexate, biologicals)] on the set of 11 VOCs (see Figure S2 ) nor on the individual discriminatory VOCs (see Table S1 ). None of the UC patients was using antibiotics at the time of VOC sampling. We could not find any relation between the discriminatory compounds identified in the present study and major differences in dietary intake in LifeLines cohort (see Table S3 ). Furthermore, individual differences in dietary intake resulting in incidental VOC changes, has in part been corrected for by including only those VOCs that were present in at least 20% of the samples. Therefore, it seems unlikely that diet did have a major impact on the identification of the discriminatory VOC pattern.
Even though the combination of all 11 VOCs yielded the highest discriminative power, we also analysed the relative importance of the individual discriminatory VOCs between active and inactive UC and found that five of 11 compounds were statistically significant between the groups (P ≤ 0.01). The AUCs of the individual discriminatory compounds ranged from 0.40 to 0.73 (see Table S2 ).
Visualisation of differences between UC and non-UC colitis based on 11 discriminatory VOCs. The ability of the identified VOC profile to distinguish UC patients and non-UC colitis patients was investigated by means of the unsupervised technique URF. Patients with active UC, UC in remission and non-UC colitis patients were found to be clearly separated using three principal components (PC1, PC2 and PC3, which are created by the combination of 11 discriminatory volatiles), which together account for more than 85% of the total variance in the data (see also Figure 2 ). The non-UC colitis patients displayed less variation than patients with active UC or UC in remission as visualised in Figure 2 , where points corresponding to non-UC colitis patients (black stars) are very close, while points related to UC remission (grey diamonds) and active UC (grey circles) disease are spread more. The homogeneity of variances was tested using the Bartlett's test statistics. The P-value of the test was <0.0001 indicating significant differences in variance between active, inactive and non-UC-colitis groups. The same test statistics delivered nonsignificant differences in variance between active and inactive UC groups. Note that the separation seen here between active and remission UC is only an estimation of the total differences seen for the entire dataset. The real accuracy of distinguishing between active and remission UC using the set of 11 VOCs is expressed as sensitivity and specificity and is provided for the validation set.
In addition, the relation between the profile of discriminatory compounds and faecal calprotectin was investigated by means of gradient boosting regression trees. 36 The result is shown in Figure S3 , where the relation between real and predicted faecal calprotectin values is displayed. The high level of agreement between real and predicted faecal calprotectin values is indicated by the R 2 equal to 0.95. This points out that there is a significant relation between volatiles readout in breath and faecal calprotectin.
Classification of non-UC-colitis using set of discriminatory VOCs. The probabilities of being assigned to active UC or UC in remission can be obtained from the K-PLS-DA classification model. These probabilities were obtained for all samples randomly selected to the internal validation set using the K-PLS-DA model based on 11 VOCs. The level of confidence between 0 and 1 of being designated to the predefined group can be obtained from these probabilities for each sample (see also Figure 3 ). The confidence level for active and inactive UC varies from 0.65 to 1, indicating high certainty of the classification model. The K-PLS-DA model, built on 11 discriminating volatiles between active and inactive UC, can also be used to calculate the confidence level of the model to designate non-UC colitis patients as active or inactive UC. The outcome is shown in Figure 4 as boxplot. The confidence level for non-UC colitis samples fluctuates around 0.5 (range 0.5-0.6). From the set of 22 non-UC colitis samples, 19 samples were predicted with a confidence level around 0.5 indicating that the classification model has no certainty for these non-UC colitis patients being active or inactive UC. Only three patients were classified as active UC with a confidence level of 0.6.
DISCUSSION
Using a metabolomics approach, we showed that VOC analysis of exhaled air has high predictive value with an AUC of 0.94 for differentiating active UC from UC patients in remission. Furthermore, the discriminating VOC profiles linked to active disease and remission in UC, are also able to differentiate active UC from patients with non-UC related colonic inflammation like diverticulitis and C. difficile infection.
We have previously shown in a large proof of principal study, that the metabolomics approach of exhaled breath analyses is a potential new tool for non-invasive assessment of mucosal inflammation in CD. 21 This study
shows that this methodology is also applicable to UC. The statistical model used in this study revealed 11 compounds, which could predict active UC with 92% sensitivity and 77% specificity. Although five single compounds out of the set of eleven did also differ between both groups, it is the entire profile that resulted in the most accurate differentiation of active and inactive UC patients. The permutation test was used to further validate the findings, indicating only 0.5% chance that the difference between active UC and UC in remission was made by chance. The set of discriminatory VOCs in breath exhibited a clear relation with faecal calprotectin, indicator of mucosal inflammation, as specified by high R
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. This finding further supports that the set of selected volatile compounds are specifically related to the inflammatory process in the bowel during active inflammation in UC. Furthermore, the correlation of faecal calprotectin and endoscopic disease activity is acceptable in active UC, which overcomes the lack of the current gold standard endoscopy in our study.
In the present study, we searched for robust markers that could distinguish between active UC and UC in remission, irrespective of differences in disease location, diet, smoking, gender and medication. As shown in the results section these factors did not show any significant influence on the set of discriminatory compounds.
Besides classification of UC related inflammation, detection of other inflammatory diseases causing colonic inflammation in patients with UC, is relevant in daily clinical practice. The risk of C. difficile infections is emerging with the worldwide increased use of antibiotics. Clostridium difficile, may contribute to exacerbations, as reported especially in the USA, and needs additional treatment. It is also increasingly recognised as secondary infection increasing the risk of more severe disease course and colectomy. 16, 17, 40 In addition, with the increasing incidence of elderly onset UC, the incidence of colonic diverticulitis will also increase in the UC population. 40, 41 The VOC analyses and statistical model used in the present study, did show that the discriminating VOCs could also distinguish between UC inflammation and non-UC related colonic inflammation. While all active UC patients showed a confidence level above 0.65 to be correctly classified, three out of 22 non-UC showed a confidence level of 0.6 (i.e. 60% change) to be falsepositively classified as active UC. Therefore, subjects with a positive profile score with 0.6 confidence level, require further clinical assessment. From the set of 11 discriminatory compounds 10 could be chemically identified. The origins of the diagnostic VOCs in breath can be derived either from the ongoing inflammatory process or being the end metabolic products of the changed microbial activity associated with the diseased condition. It is known that the microbiome in the gut changes during stages of inactive and active disease in IBD. The majority of the discriminating VOCs in our study are hydrocarbons, which are probably produced during the process of reactive oxygen species induced lipid peroxidation. Several studies show that free oxygen radical production plays an important role in the pathophysiology of IBD. 43, 44 Furthermore, the level of acetic acid was found to be reduced in the exhaled breath of UC patients with active disease. Acetic acid is a short chain fatty acid produced by the fermentation of carbohydrates by several bacteria (especially within the Firmicutes phylum) and can therefore be related to changes in the gut microbiota during the inflammatory process. 28 Remarkably, the discriminatory VOC profile for distinguishing active and inactive UC differed from the set found in active vs. inactive CD, though most VOCs in both studies are related to lipid peroxidation due to oxidative stress. 21 This is in line with findings that,for example, microbial perturbations differ between UC and CD 45 and supports that UC and CD should be considered as separate clinical entities. Furthermore, the VOC profile for active UC vs. remission did also not overlap with VOCs that could discriminate between UC and healthy controls (data not shown).
In recent years, some other studies on VOCs analyses in IBD have been published. It should however be mentioned that most of them addressed different VOC profiles between IBD patients and healthy controls or between CD and UC patients, and were not designed to look for discriminatory profiles between active disease and remission. One study analysing breath VOC profiles by selective ion flow tube mass spectroscopy in children with IBD, could not find differences between CD and UC patients, nor between active disease and remission disease based on clinical and biochemical parameters. 46 This may be due to the relatively small numbers of UC patients (N = 11), of which only 20% had active disease. Besides breath VOCs, also faecal and urinary VOCs have been studied for their potential as biomarkers in IBD. Ahmed et al. could clearly separate adult CD patients with active and inactive disease and healthy controls with analysis of faecal headspace VOCs, but VOC profiles in active vs. quiescent UC patients showed significant overlap. The authors suggest that the difference in test performance between CD and UC could be related to the different types of inflammation (transmural vs. superficial) and the degree of microbial perturbations which they considered to be more pronounced in CD. 47 In a study on urinary headspace VOC analysis with electronic nose and Field Asymmetric Ion Mobility Spectrometry, active disease based on clinical parameters could be distinguished from disease in remission in both CD and UC with approximately 75% accuracy. 48 These studies support the potential of metabolome analysis for non-invasive assessment of mucosal inflammation and subsequent clinical disease activity in IBD.
Some limitations of our study should be noted. Endoscopic disease activity, the standard for evaluation of mucosal inflammation, was not routinely available, as this is not feasible in a large follow-up cohort of daily clinical practice. Instead we used a second best, but stringent definition of active disease or remission, based on two non-invasive disease activity markers and a clinical sore. We have deliberately chosen to include only UC patients with clearly defined active disease or remission in the absence of endoscopy scores, and therefore, we do not expect that this has influenced the results of our study. The strength of the study is the inclusion of a set of non-UC colitis patients, but it should be mentioned that the number of these patients was limited (N = 22) and comprised patients with divers non-UC colitis aetiology. Despite the small number and mixed disease type in this group, a clear and highly accurate distinction could be made between these patients and UC patients with active disease or remission based on the VOCs profile. Although these results need validation in an independent second large cohort, preferably against endoscopy as "gold standard", the current data clearly show the potential of VOCs profile analysis as sensitive and specific marker for the diagnosis of active UC vs. UC in remission and for the differentiation between active UC and non-UC colitis.
In the optimal management of IBD, regular monitoring of mucosal inflammation is mandatory and new diagnostic modalities for accurate and repeated assessment of inflammation are warranted. Breath analysis could be an ideal diagnostic modality for application in future tele-monitoring programs, facilitating continuous care and patient empowerment and possibly improve the outcome of chronic diseases like IBD. 49 In conclusion, we clearly show that VOCs in exhaled breath can accurately differentiate between active and inactive disease in UC, and is also able to discriminate UC from non-UC related colonic inflammation, and is therefore a potential new non-invasive biomarker for active disease in UC. Breath testing could be the ideal future diagnostic modality for at home monitoring of IBD patients. Furthermore, VOCs profile analysis can also select UC patients with symptoms suggestive of an UC flare with a negative VOCs profile, and thereby trigger further investigation for other causes of bowel inflammation.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article: Table S1 . The significance level (P-values) of individual discriminatory volatile organic compounds (VOCs) tested for clinical factors using the Kruskal-Wallis test with a Benjamini-Hochberg post hoc correction together with Cohen's d effect size index # . As can be seen none of the individual VOCs are significant. Table S2 . The area under the curve (AUC) of receiver operating characteristic curve of individual discriminatory VOCs. The AUC ranges from 0.40 to 0.73 for the set of discriminatory compounds. Table S3 . The averaged values and standard deviation of individual discriminatory VOCs in breath for subjects following a specific diet (group 1) and subjects without any restrictions in the diet (group 2). The difference between group 1 and group 2, designated as p-value, was tested by Mann-Whitney U test with Benjamini-Hochberg post hoc correction. There are no statistically significant differences between group 1 and group 2. Figure S1 . ROC curve for the independent validation set of the kernel partial least square discriminatory analysis model for active and inactive UC based on 11 discriminating VOCs. AUC is 0.94 (95% confidence interval 0.91-0.97). Figure S2 . Boxplots of discriminatory VOCs profile showing the differences in gender, smoking habit, disease extent and medication respectively. For each box, the mean intensity of all 11 volatile compounds was calculated taking into account all 132 analysed samples. The statistical significance of the external factors was investigated by means regularised MANOVA. For each studied factor, the exact P-value obtained from rMANOVA is given. As can be seen, there are no significant differences between the levels of the discriminatory set of VOCs and the shown factors. Figure S3 . The relation between real faecal calprotectin values and the predicted value obtained by Gradient Boosting Regression Trees using a set of 11 discriminatory volatile organic compounds. The high level of agreement between real and predicted values is indicated by the R 2 equal to 0.95. This indicates that there is a relation between volatiles readout in breath and faecal calprotectin. The faecal calprotectin is shown in logarithmic scale. 
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